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Abstract 
The Joint United Nations Programme on HIV and AIDS (UNAIDS) has set a new 90-90-90 global target for the coverage of 
anti-retroviral therapy (ART) to be reached by 2020. This would mean that 90% of all people infected with HIV know their 
status, 90% of them are on ART and 90% of them will have full viral load suppression. Here we first estimate the case 
reproduction number, R0, for countries in sub-Saharan Africa and for India using data on the rate at which the prevalence of 
HIV increased at the start of the epidemic and the life expectancy of people living with HIV who are not on ART. R0 
determines the magnitude of the control problem, that is to say, the extent to which transmission must be reduced to eliminate 
HIV. We show that in sub-Saharan Africa the median value of R0 is 4.6 and in all but five countries R0 is less than 6.3. If the 
90-90-90 target is reached, 73% of all those living with HIV will have full viral load suppression. If this is maintained it should 
guarantee elimination in 70% of all countries in sub-Saharan Africa and will reduce R0 to less than 2 in the remaining 12 
countries, making elimination easy to achieve by increasing the availability of other high impact methods of prevention.  
 
Introduction 
The International AIDS Society recommends immediate 
treatment with anti-retroviral therapy (ART) for all HIV 
positive people irrespective of their CD4+ cell count.1 With 
good compliance this will reduce their viral load to less 
than 100 cells/μL within about 4 weeks2 and will reduce 
their infectiousness to others by 96% or more.3-5 With high 
levels of ART coverage it should be possible to reduce the 
case reproduction number, R0, to less than 1 and eliminate 
HIV.6 
 Here we use data on the rate of increase of the 
prevalence of HIV at the start of the epidemics in sub-
Saharan African countries to estimate R0 and determine the 
extent to which transmission must be reduced if HIV is to 
be eliminated. This enables us to assess the likely impact on 
the epidemic of reaching the UNAIDS recommended 90-
90-90 treatment target. 
Methods 
At the start of the epidemic of HIV, in the simplest 
dynamical model, each infected people infect other people 
at a per capita rate β and die at a per capita rate μ. The 
prevalence of infection then increases at a rate ρ = β − μ 
and the case reproduction number, R0, is given by 
 0 0 e
tR dt βμ μβ
∞ −= =∫ . 1 
so that  
 0R
ρ μ
μ
+=  2 
 In practice, mortality in people infected with HIV is not 
constant but increases approximately linearly with time 
since infection. We wish to find an expression relating R0 
to the initial growth rate and the mortality rate for HIV in 
this more general case. 
 The best data for survival as a function of the age at 
infection and the time since infection with HIV are from the 
CASCADE study7 (Figure 1). The data in Figure 1 can be 
fitted to within the statistical errors by a Γ-distribution, 
Γ(s,k), where s determines the shape and k determines the 
scale of the distribution. Imposing the same shape 
parameter for all ages gives the fits shown in Figure 1, 
where the best fit value of the shape parameter is 3.74 
(3.66−3.82). The mean value of the survival for Γ(s,k) is m 
= sk and these values are plotted in  
Figure 2. The best fit straight line to the data in  
Figure 2 has an intercept at age 0 years of 18.67 years and a 
slope of −0.201.* 
 
 
 
 
 
 
 
 
 
Figure 1. Survival of HIV-positive people as a function of 
time since infection for people infected at different ages. 
Orange: 0−5 yrs; brown: 5−15 yrs; grey: 15−25; green: 
25−35 yrs; blue: 35−45 yrs; purple: 45−55 years; pink: 
55−65 yrs; black: 65−75 yrs.7 
 
 
 
 
 
 
 
 
Figure 2. Mean survival for HIV-positive people, not 
on ART, as a function of age at infection.7 
                                                          
*  Note that those in the youngest age group (0−5 yrs) were infected 
through blood-transfusions, not vertically from their mothers at birth. 
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 We first determine the relationship between the 
epidemic growth rate, ρ, the mean survival, m, and the rate 
at which new cases are generated, β, for different values of 
the shape parameter s. In order to do this we note that for a 
series of Poisson processes, with s successive states, in 
which the transition rate from one state to the next is 1/k, 
the distribution of time to leaving the last state is Γ(s,k). We 
set up the transition matrix for this process and the principle 
eigenvector gives the initial rate of increase. 
 We consider what happens as we increase the shape 
parameter. In general we have 
 0 0 ( , )R s k tdtβ
∞= Γ∫  3 
 0R skβ=  4 
so that changing s does not change R0 provided we keep the 
mean survival time, sk, constant. However, if we change s 
then the relationship between the growth rate, the force of 
infection and the mean survival, β = ρ + μ, no longer holds. 
For a given value of R0 the growth rate will increase as s 
increases because there is an increasing time delay between 
new infections and deaths. If we ignore this correction we 
will overestimate R0 for a given growth rate. We therefore 
seek an expression for R0 of the form 
 0
cR ρ μμ
+=  5 
and we choose the correction factor c that gives the best 
estimates of R0 for different values of ρ and μ. 
 To estimate c we proceeded as follows. We set up the 
growth rate matrix for an SI model with either 3 or 4 
infectious stages since we want to estimate c for s = 3.74. 
We then set μ = 0.1/year, corresponding to a life-
expectancy of ten years, and vary R0 from 1 to 10 in steps 
of 1 so that β varies from 0.1 to 1 in steps of 1 and for each 
value of R0 and for s = 3 and 4 we calculate the principle 
eigenvalue of the growth rate matrix for a given value of 
the correction factor c. We then regress R0, calculated from 
Equation 5, against the true value, calculated from Equation 
1, by minimizing the maximum absolute value of the error 
expressed as a percentage of the true value. The mini-max 
estimate of c = 0.831 and the maximum fractional error in 
the estimates of R0 are all less then 8%. We therefore have 
as our best estimate of R0 
 0.831 0.5760 0.6091 1 1d d
nR ρμ μ= + = + = +  6 
where we have given alternative expressions for R0 noting 
that c = 0.831, the doubling time d = ln(2)/ρ = 0.693/ρ and 
the median survival time, n, for the Γ-distribution is8 
 3 0.8
3 0.2
sn m s
−≈ −  7 
so that for s = 3.74 n ≈ 0.946/μ . 
 Finally, we note that the best fit value of c also depends 
on the value of μ which varies significantly with the age at 
infection (Figure 2). We therefore repeat the calculations 
but with a mean survival of 5 years and 20 years. Equation 
6 still gives estimates of R0 that are within 8% of the 
correct value when m is set to 5 years and to within 12% of 
the correct value when m is set to 20 years. 
Results 
Table 1 gives the estimated doubling times for the 
prevalence of HIV at the start of the epidemic9 and  
Figure 2 shows that the median survival of 30 year old HIV 
positive people who are not on ART is 12.3 years. Equation 
6 then gives the estimated values of R0 (Table 1) and the 
minimum and maximum values and three percentiles 
(Table 2).  
Table 1. Initial doubling times, d, and the corresponding values of 
R0 for HIV in sub-Saharan African countries and India. 
Country d (yrs) R0 Country d (yrs) R0 
Angola 1.77 4.80 Lesotho 1.01 7.99 
Benin 1.63 5.20 Liberia 0.89 8.93 
Botswana 1.65 5.15 Madagascar • • 
Burkina Faso 1.66 5.10 Malawi 1.95 4.62 
Burundi 2.05 4.14 Mali 1.23 6.74 
Cameroon 1.51 5.61 Mozambique 2.00 4.53 
CA Republic 1.69 5.02 Namibia 1.92 4.68 
Chad 3.31 2.56 Niger 1.89 4.74 
Congo 4.31 1.97 Nigeria 1.17 7.03 
Côte d’Ivoire 1.75 4.84 Rwanda 3.26 3.17 
Djibouti 2.06 4.13 Senegal 3.30 3.14 
DR Congo • • Sierra Leone 1.52 5.65 
Equat. Guinea 2.73 3.10 Somalia 5.26 2.34 
Eritrea 1.73 4.89 South Africa 1.47 5.80 
Ethiopia 1.55 5.46 Sudan 5.23 2.35 
Gabon 1.93 4.40 Swaziland 1.96 4.60 
Gambia 4.39 1.94 Togo 1.64 5.31 
Ghana 1.81 4.68 Uganda 3.11 3.27 
Guinea 1.94 4.38 UR Tanzania 2.03 4.48 
Guinea-Bissau 2.52 3.37 Zambia 3.23 3.19 
India 1.79 4.74 Zimbabwe 1.66 5.25 
Kenya 1.34 6.34    
  
Table 2. The minimum and maximum values 
and the 10%, 50% and 90% percentiles for R0 in 
sub-Saharan African countries. The right hand 
column gives the incidence rate ratio, IRR, for 
those on ART needed to eliminate HIV. 
Percentile R0 IRR 
Minimum 2.34 0.43 
10% 2.55 0.39 
50% 4.57 0.22 
90% 7.31 0.14 
Maximum 8.93 0.11 
  
 The median value of R0 is 4.6 and 90% of the estimates 
are less than 7.3. The five countries with the highest 
estimated values of R0 are Kenya, Lesotho, Liberia, Mali 
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and Nigeria. In Kenya the early prevalence estimates were 
based on data from a small but increasing number of ante-
natal clinics and may not have been representative of the 
country as a whole. In Lesotho the data are more reliable 
but the epidemic there was driven in the early stages by 
migrant labour to the mines in South Africa and may have 
risen faster than otherwise expected. In Liberia, Mali and 
Nigeria the peak prevalence was less than 4% so that 
estimates of early epidemic trends may also be unreliable. 
Discussion 
The median value of R0 in sub-Saharan African countries is 
4.6 so that to eliminate HIV in half of the countries in sub-
Saharan Africa it will be necessary to reduce transmission 
by 78%; the 90th percentile value of R0 is 7.3 so that to 
eliminate HIV in 90% of the countries in Africa it will be 
necessary to reduce transmission by 86%. Reaching the 
UNAIDS 90-90-90 treatment target for 2020 in which 90% 
of people infected with HIV know their status, 90% of 
these are on treatment and 90% of these have full viral load 
suppression will reduce transmission by73% and guarantee 
elimination in 70% of all countries in sub-Saharan Africa 
and in India. It would also reduce R0 to less than 2 in the 
remaining 30% of countries.  
 In several countries in sub-Saharan Africa the 
prevalence of HIV fell markedly before ART became 
widely available, suggesting  that there must have been a 
significant reduction in transmission before ART became 
available.9 Combined with further increases in the coverage 
of high impact interventions such as male circumcision and 
pre-exposure prophylaxis for sex-workers and others at 
high risk, reaching the UNAIDS target for coverage of 
ART should almost certainly lead to the eventual 
elimination of new infections in all of sub-Saharan Africa 
and in India.   
 In African countries elimination of HIV will depend on 
frequent and widespread testing for HIV and high rates of 
compliance with ART. Other prevention methods including 
male circumcision, pre-exposure prophylaxis, treating 
curable sexually transmitted diseases, condom use 
promotion and behaviour change programmes will not, in 
themselves, be sufficient to eliminate HIV, but may make 
an important contribution to early treatment with ART. 
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